An interventional study of Empowerment and personal transformation intervention in HIV, sponsored by Mbarara University of Science and Technology. Completed at 1 site in Uganda. Open to participants aged 15 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Mbarara University of Science and Technology · Not applicable, Interventional, and Health services research
There are over 73,000 adolescents living with HIV (ALHIV) in Uganda constituting 4% of the worldwide population of ALHIV. HIV remains a leading cause of death among adolescents despite widespread availability of antiretroviral medication. Generally, ALHIV have poor outcomes with higher rates of loss to follow up compared with other age groups. Mortality rates and loss to follow up are highest during the transition period. Transition success may be maximized for ALHIV who are better prepared to negotiate care in adult HIV clinic settings. This study proposes to develop a self-management intervention for ALHIV transitioning to adult HIV care and test the impacts of the intervention on HIV outcomes. Conducting the proposed studies in this application will complement my prior training in psychiatry while filling key gaps in three areas: (a) behavioral science theories and their application to behavioral interventions, (b) adaptation and design of behavioral interventions, and (c) testing of behavioral interventions through randomized trials. To fill these gaps, the investigators will conduct qualitative research to elaborate a conceptual framework of the barriers faced by ALHIV transitioning to adult HIV care in Uganda (Aim 1), develop a self-management intervention that will enable ALHIV to successfully transition to adult HIV care (Aim 2), and assess feasibility, acceptability, and preliminary effects of the self-management intervention on HIV outcomes for ALHIV transitioning to adult HIV care (Aim 3). This study will be the first to develop a self-management intervention targeting the critical transition period from pediatric to adult HIV care in sub-Saharan Africa and the first to use a randomized design to test the effect of a self-management intervention on health outcomes among ALHIV in Uganda who are transitioning to adult HIV care. These findings will have significant public health impact by optimizing health outcomes for a key population in the global HIV epidemic. The proposed research will serve as the basis for a competitive R01 grant proposal, submitted in year 4, to conduct a fully-powered, randomized controlled trial to evaluate the effectiveness of a behavioral intervention to improve retention in care and viral suppression among ALHIV in Uganda who are navigating the critical period of transition to adult HIV care.
HIV is a leading cause of mortality among adolescents living with HIV (ALHIV) in sub-Saharan Africa. Mortality among ALHIV is attributed to disengagement from care and poor adherence to HIV medications . Rates of retention in care and adherence to ART are lowest among ALHIV compared to other age groups. The risks of disengagement from care, being lost to follow up, and mortality rates are highest during the transition from pediatric to adult HIV care.
The study proposes to achieve the following aims:
Aim 1: Use qualitative research to develop a conceptual framework of the barriers faced by ALHIV transitioning to adult HIV care in Uganda. The investigators will conduct in-depth qualitative interviews with a purposive sample of ALHIV before adult HIV care transition (n=15) and after transition (including both those lost to follow-up and those successfully retained in care; n=15), caregivers (n=20), and healthcare providers (n=10). Interviews will focus on barriers to successful transition and potential facilitators and interventions.
Aim 2: Develop a self-management intervention that will enable ALHIV to successfully transition to adult HIV care. The initial content of the intervention will be based on the qualitative data from Aim 1. Based on my preliminary data and existing research, the investigators anticipate that the intervention will include 6 weekly sessions and involve elements of psychoeducation, cognitive behavioral strategies, self-efficacy training, problem solving, and resilience strengthening. Final intervention content will be refined in focus group discussions with ALHIV (n=10), caregivers (n=10), and health care providers (n=10).
Aim 3: Assess feasibility, acceptability, and preliminary effects of the self-management intervention on HIV outcomes for ALHIV transitioning to adult HIV care. The investigators will conduct a pilot randomized controlled trial with 80 ALHIV who will have been identified by their pediatric providers for transition to adult HIV care; 40 will be randomly assigned to the self-management intervention and 40 will be assigned to standard of care. Outcomes will be assessed at pre-intervention baseline, at 6 weeks (immediately post-intervention), and at 6 months post-intervention follow-up. The primary outcomes will be treatment adherence (based on pharmacy refill, pill count, and self-report), engagement in care, and adherence self-efficacy. Secondary outcomes will include acceptability and feasibility of the intervention, internalized/anticipated HIV stigma, depression, problem solving skills, quality of life, viral load suppression, and retention in care.
Mbarara University of Science and Technology is the lead sponsor of 31 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control condition: The control condition will be standard of care. This will include regular review in the clinic for medical refills and adherence counseling that will be given in the clinic as required and determined by the attending clinicians and the counselors in the HIV clinic. The clinic visits will be guided by the clinical status, availability of school programs, distance from the clinic, and ability to afford transport fare to the clinic.
Intervention/Treatment: The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
Behavioral: Empowerment and personal transformation intervention
The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
Mean adherence
Treatment adherence based on unannounced pill counts. Pill count adherence will be calculated as (the number of pills dispensed) minus (number of pills counted) divided by (the number of pills expected to be taken) in the previous month.
Time frame: 6 months
Mean transition readiness score
The investigators will measure transition readiness using the HIV Adolescent Readiness for Transition Scale, which is a 15-item transition readiness scale that measures transition readiness among adolescents living with HIV.
Time frame: 6 months
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mbarara University of Science and Technology